Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia (Q36758604)

16 August 2017

1 reference

title

Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia (English)

1 reference

16 August 2017

0 references

Yesid Alvarado

1

1 reference

16 August 2017

Effrosyni Apostolidou

series ordinal

2

1 reference

16 August 2017

Ronan Swords

series ordinal

3

1 reference

16 August 2017

Francis J Giles

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Emerging Drugs

16 August 2017

1 reference

16 August 2017

12

1 reference

16 August 2017

1

1 reference

16 August 2017

165-179

1 reference

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

The biology of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Salvage therapy for refractory or relapsed acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

AMN107: tightening the grip of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Roots of clinical resistance to STI-571 cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Novel tyrosine kinase inhibitors in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Two distinct phosphorylation pathways have additive effects on Abl family kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Src family tyrosine kinases and growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Aurora A and B kinases as targets for cancer: will they be selective for tumors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Janus kinase 2: a critical target in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Cell death induced by vincristine in the intestinal crypts of mice and in a human Burkitt's lymphoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: mechanism of inoculum effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Eradication of minimal residual disease in hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Oxyhalogenation of glycals for the synthesis of anti-tumor-active 2'-halo daunorubicin analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Pemetrexed and its emerging role in the treatment of thoracic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

The biology of the combretastatins as tumour vascular targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Novel sulfonate derivatives: potent antimitotic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Structure of the alpha beta tubulin dimer by electron crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Localization of the colchicine-binding site of tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

BONE-MARROW TRANSPLANTATION IN HIGH-RISK ACUTE LYMPHOBLASTIC LEUKAEMIA IN FIRST AND SECOND REMISSION

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.165

10.1517/14728214.12.1.165

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference